To date, many studies have shown that the use of 5-aza, a DNMT inhibitor, and TSA, a HDAC inhibitor, can reactivate the expression of ERα in ERα-negative breast cancer cells, further strengthening the role of epigenetic mechanisms in regulating and driving cancers [11, 19]. This evidence concerns the gene HDAC9 and breast carcinoma.